Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive UST Platform and Agrochem Asset Acquisition Update, Followed by a Q&A Session, on Wednesday, July 21, 2021
SOUTH EASTON, MA / ACCESSWIRE / July 20, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences, agriculture, food & beverage, and other key industries, today announced the Company's participation in the July 21st Emerging Growth Conference. This real-time, interactive investor conference will feature 11 companies, presenting for 30-45 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, has been asked to lead off the conference and to expand on the Company's recently reported long-term CBD stability and Astaxanthin processing breakthroughs using its Ultra Shear Technology™ (UST™) nanoemulsification platform. Mr. Schumacher will also present an update on its impending acquisition of assets of a global eco-friendly agrochemicals company. Mr. Schumacher's presentation information is below:
DATE: Wednesday, July 21, 2021 (9:30 am EDT)
PRESENTATION: Video Webcast
REGISTER: Click here to register for the conference
Highlights of Recent Press Release on UST Nanoemulsification of Astaxanthin
- Astaxanthin is considered one of the world's most potent antioxidants
- Applications span pharmaceutical, nutraceutical, cosmetic, food & beverage, and animal feed industries
- As an antioxidant, it is more potent than Vitamin C (6,000x), Coenzyme Q (800x), and Vitamin E (100x)
- It is plant oil based, which makes it difficult to absorb by humans/animals when taken as a supplement
- UST-processed nanoemulsions of Astaxanthin oil would significantly increase its water solubility and bioavailability, extend its shelf-life, allow for more precise dosing, and save costs for manufacturers/consumers
- The worldwide market for Astaxanthin was estimated to be $1 billion in 2019
Highlights of Recent Press Release on Achievement of Over One Year Shelf-life of UST Nanoemulsified CBD Oil
- Many vitamins and other dietary supplements are oil-based and thus difficult for humans/animals to absorb
- Science has shown that that oil-based products processed to the nano-level (nanoemulsions) are significantly more water soluble, bioavailable, and long-term stable
- True long-term stable nanoemulsions are difficult to make, especially at large, commercial scale
- UST processed nanoemulsions of CBD oil in water were shown to soar past PBI's one-year stability goal, with over 14 months of long-term stability
- Such rock-solid stability opens up explosive growth potential for UST-processed CBD-infused beverages
- The CBD market is expected to grow to approximately $13 Billion by 2028
About EmergingGrowth.com & the Emerging Growth Conference
Founded in 2009, EmergingGrowth.com quickly became a leading, independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content in identifying emerging growth companies and markets that can be overlooked by the investment community.
The Emerging Growth Conference has proven to be an effective way for publicly traded companies to present and communicate new products, services, and other major announcements to the investment community in an effective and time efficient manner. The audience includes potentially thousands of individual and institutional investors, as well as investment advisors and analysts.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Ourprimary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g.,oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, youcan identify forward-looking statements by terminology such as "may," "will," "should,""could,""would," "expects," "plans," "intends,""anticipates," "believes," estimates,""predicts," "projects,""potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not placeundue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially fromany forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T)
SOURCE: Pressure BioSciences Inc.